112 related articles for article (PubMed ID: 22027692)
1. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.
Zhang Y; Castaneda S; Dumble M; Wang M; Mileski M; Qu Z; Kim S; Shi V; Kraft P; Gao Y; Pak J; Sapra P; Bandaru R; Zhao H; Vessella RL; Horak ID; Greenberger LM
Mol Cancer Ther; 2011 Dec; 10(12):2309-19. PubMed ID: 22027692
[TBL] [Abstract][Full Text] [Related]
2. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.
Bianchini D; Omlin A; Pezaro C; Lorente D; Ferraldeschi R; Mukherji D; Crespo M; Figueiredo I; Miranda S; Riisnaes R; Zivi A; Buchbinder A; Rathkopf DE; Attard G; Scher HI; de Bono J; Danila DC
Br J Cancer; 2013 Nov; 109(10):2579-86. PubMed ID: 24169353
[TBL] [Abstract][Full Text] [Related]
3. Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.
Recouvreux MV; Wu JB; Gao AC; Zonis S; Chesnokova V; Bhowmick N; Chung LW; Melmed S
Endocrinology; 2017 Jul; 158(7):2255-2268. PubMed ID: 28444169
[TBL] [Abstract][Full Text] [Related]
4. Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion.
Shih TC; Liu R; Wu CT; Li X; Xiao W; Deng X; Kiss S; Wang T; Chen XJ; Carney R; Kung HJ; Duan Y; Ghosh PM; Lam KS
Clin Cancer Res; 2018 Sep; 24(17):4319-4331. PubMed ID: 29666302
[No Abstract] [Full Text] [Related]
5. Androgen receptor transcriptional activity is required for heregulin-1β-mediated nuclear localization of the HER3/ErbB3 receptor tyrosine kinase.
Jathal MK; Siddiqui S; Vasilatis DM; Durbin Johnson BP; Drake C; Mooso BA; D'Abronzo LS; Batra N; Mudryj M; Ghosh PM
J Biol Chem; 2023 Aug; 299(8):104973. PubMed ID: 37380074
[TBL] [Abstract][Full Text] [Related]
6. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
Sun S; Sprenger CC; Vessella RL; Haugk K; Soriano K; Mostaghel EA; Page ST; Coleman IM; Nguyen HM; Sun H; Nelson PS; Plymate SR
J Clin Invest; 2010 Aug; 120(8):2715-30. PubMed ID: 20644256
[TBL] [Abstract][Full Text] [Related]
7. Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer.
Sharifi N; Hurt EM; Thomas SB; Farrar WL
Clin Cancer Res; 2008 Oct; 14(19):6073-80. PubMed ID: 18829485
[TBL] [Abstract][Full Text] [Related]
8. Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium.
Lim M; Otto-Duessel M; He M; Su L; Nguyen D; Chin E; Alliston T; Jones JO
ACS Chem Biol; 2014 Mar; 9(3):692-702. PubMed ID: 24354286
[TBL] [Abstract][Full Text] [Related]
9. Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy.
Muralidhar A; Gamat-Huber M; Vakkalanka S; McNeel DG
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38772685
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor antagonists in castration-resistant prostate cancer.
Rathkopf D; Scher HI
Cancer J; 2013; 19(1):43-9. PubMed ID: 23337756
[TBL] [Abstract][Full Text] [Related]
11. Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model.
Mout L; de Wit R; Stuurman D; Verhoef E; Mathijssen R; de Ridder C; Lolkema M; van Weerden W
EBioMedicine; 2018 Jan; 27():182-186. PubMed ID: 29276148
[TBL] [Abstract][Full Text] [Related]
12. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.
Attard G; Richards J; de Bono JS
Clin Cancer Res; 2011 Apr; 17(7):1649-57. PubMed ID: 21372223
[TBL] [Abstract][Full Text] [Related]
13. Targeting the androgen receptor pathway in prostate cancer.
Chen Y; Sawyers CL; Scher HI
Curr Opin Pharmacol; 2008 Aug; 8(4):440-8. PubMed ID: 18674639
[TBL] [Abstract][Full Text] [Related]
14. A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer.
Ylitalo EB; Thysell E; Landfors M; Brattsand M; Jernberg E; Crnalic S; Widmark A; Hultdin M; Bergh A; Degerman S; Wikström P
Clin Epigenetics; 2021 Jun; 13(1):133. PubMed ID: 34193246
[TBL] [Abstract][Full Text] [Related]
15. Revealing the mechanism of ethyl acetate extracts of Semen Impatientis against prostate cancer based on network pharmacology and transcriptomics.
Hu B; Wang C; Wu Y; Han C; Liu J; Chen R; Wang T
J Ethnopharmacol; 2024 Aug; 330():118228. PubMed ID: 38643863
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer.
Tiwari R; Manzar N; Bhatia V; Yadav A; Nengroo MA; Datta D; Carskadon S; Gupta N; Sigouros M; Khani F; Poutanen M; Zoubeidi A; Beltran H; Palanisamy N; Ateeq B
Nat Commun; 2020 Jan; 11(1):384. PubMed ID: 31959826
[TBL] [Abstract][Full Text] [Related]
17. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer.
Reyes EE; VanderWeele DJ; Isikbay M; Duggan R; Campanile A; Stadler WM; Vander Griend DJ; Szmulewitz RZ
J Transl Med; 2014 Nov; 12():313. PubMed ID: 25424879
[TBL] [Abstract][Full Text] [Related]
18. Poly-glutamine-dependent self-association as a potential mechanism for regulation of androgen receptor activity.
Roggero CM; Esser V; Duan L; Rice AM; Ma S; Raj GV; Rosen MK; Liu ZP; Rizo J
PLoS One; 2022; 17(1):e0258876. PubMed ID: 34986150
[TBL] [Abstract][Full Text] [Related]
19. Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.
Chen M; Adeniji AO; Twenter BM; Winkler JD; Christianson DW; Penning TM
Bioorg Med Chem Lett; 2012 May; 22(10):3492-7. PubMed ID: 22507964
[TBL] [Abstract][Full Text] [Related]
20. 5alphaDH-DOC (5alpha-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer.
Uemura M; Honma S; Chung S; Takata R; Furihata M; Nishimura K; Nonomura N; Nasu Y; Miki T; Shuin T; Fujioka T; Okuyama A; Nakamura Y; Nakagawa H
Cancer Sci; 2010 Aug; 101(8):1897-904. PubMed ID: 20560974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]